A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer

Inclusion Criteria: 1. Sign informed consent and join the study voluntarily; 2. Patients diagnosed with extensive small cell lung cancer; 3. Age ≥18 years old; 4. Have at least one measurable lesion (according to RECIST 1.1); 5. The investigators judged that adebrelimab treatment was acceptable; 6. Contraception: Patients should agree that it must be used during the study period and within 6 months after the study ends Effective contraception; Exclusion Criteria: 1. Allergic to adebrelimab and its excipients; 2. Patients who have also received other immune drugs or therapies; 3. Patients who are participating in other interventional studies; 4. patients with other malignant tumors; 5. Pregnant or lactating women; 6. The investigator considers that the patient is not suitable to participate in any other conditions of the study.